Status:
WITHDRAWN
Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors
Lead Sponsor:
Hadassah Medical Organization
Collaborating Sponsors:
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Conditions:
Metastatic Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study ...
Eligibility Criteria
Inclusion
- Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.
Exclusion
- Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.
Key Trial Info
Start Date :
July 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2005
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00148993
Start Date
July 1 1998
End Date
July 1 2005
Last Update
April 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Tel Aviv, Israel, 64239